Ten things you should know about protein kinases: IUPHAR Review 14 - Test2 - elhamkhani - TriplyDB

Ten things you should know about protein kinases: IUPHAR Review 14

Ten things you should know about protein kinases: IUPHAR Review 14

http://www.wikidata.org/entity/Q26849417

about

The expanding role of immunopharmacology: IUPHAR Review 16 Unraveling the Anticancer Effect of Curcumin and Resveratrol Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy The New Role for an Old Kinase: Protein Kinase CK2 Regulates Metal Ion Transport Pragmatic medicine in solid cancer: a translational alternative to precision medicine The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands Targeting kinase signaling pathways with constrained peptide scaffolds.Screening and identification of novel biologically active natural compounds.The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins.Progress towards a public chemogenomic set for protein kinases and a call for contributions.Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates.Diverse Molecular Targets for Chalcones with Varied Bioactivities.Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.Rewiring the solid tumor epigenome for cancer therapy.Advances of small molecule targeting of kinases.Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.Phosphorylation, Signaling, and Cancer: Targets and Targeting.Drug target ontology to classify and integrate drug discovery data.The target landscape of clinical kinase drugs.Kinase-targeted cancer therapies: progress, challenges and future directions.Structural pliability adjacent to the kinase domain highlights contribution of FAK1 IDRs to cytoskeletal remodeling.KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking.New opportunities for kinase drug repurposing and target discovery.mus-52 disruption and metabolic regulation in Neurospora crassa: Transcriptional responses to extracellular phosphate availability.Characterization of Covalent-Reversible EGFR Inhibitors.

P2860

Q26801862-05A1398E-6E9C-4FBB-98F1-5E2F05F71ACE Q28073155-92F766AE-56EC-4DD8-842C-0B6BD2426CCA Q28076097-3FDA5D01-6094-4C95-B120-AE64CCFBE2C9 Q28077409-50B1CC50-95A7-4FE5-962B-F9F873127416 Q28391863-089EB3E9-7A86-421A-96EF-1AC135E5E415 Q28603128-03AA69E4-BB50-453F-BCE2-43112C049C45 Q30398451-44B6A473-E4BB-4BDE-B64F-1C6BEB44A873 Q33777835-E62A2F29-9930-41B0-86B8-49BEBD94B662 Q37060125-E0394170-EE8C-40C4-91B6-6D084DA4E2CC Q38646648-6CC687A5-3B0A-406E-AD7F-7FEBDEE85F98 Q38685553-076FD4DA-4557-4BA6-AD1A-94B5B1694E6E Q38697065-865A6A87-043D-4786-A693-2A00E9E53290 Q38707609-857A61AC-9E56-4B6D-BC4B-E2B36A625812 Q38882099-42DCF8B1-1436-40F1-9661-4E2FCF09299B Q38895216-16C6F13F-D639-41DE-A944-633217DC1479 Q39450797-1AE3C6D2-27EB-4013-9A52-16A8ECB89ED4 Q41909845-5450E5BF-9A7B-419A-93B6-E6A2D6D6E315 Q43189953-1E58F317-199C-4E22-A7E5-3E38FA02D535 Q46264677-23622C79-07DE-47F6-B02D-DC685E101ABA Q47345032-68FEFD10-E2B2-4F2F-BFE8-CC29C0F54653 Q49887882-50E5C6D4-7BEF-495A-9DE1-514881B8497E Q51414693-2809E80E-C9A1-43C2-B031-FDB4335EC804 Q52597351-7DB12D2C-CF69-4AA2-8007-7409324947FB Q52653202-9EF076CE-7FA5-4086-8570-1FA6B4A3E268 Q52691433-CE1E7D51-87E5-48C7-9263-DF1A448560DE Q55317607-B368ACD3-6854-4355-B777-4FC7DD41DAC0

P2860

Ten things you should know about protein kinases: IUPHAR Review 14

http://www.wikidata.org/entity/Q26849417

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Ten things you should know about protein kinases: IUPHAR Review 14

@ast

Ten things you should know about protein kinases: IUPHAR Review 14

@en

Ten things you should know about protein kinases: IUPHAR Review 14

@nl

type

label

Ten things you should know about protein kinases: IUPHAR Review 14

@ast

Ten things you should know about protein kinases: IUPHAR Review 14

@en

Ten things you should know about protein kinases: IUPHAR Review 14

@nl

prefLabel

Ten things you should know about protein kinases: IUPHAR Review 14

@ast

Ten things you should know about protein kinases: IUPHAR Review 14

@en

Ten things you should know about protein kinases: IUPHAR Review 14

@nl

P1433

Q26849417-44D4839B-1026-4C2D-9110-639B768A4A15

P1476

Q26849417-5BB64011-FC43-409C-8F60-BC738AD8EEDD

P2093

Q26849417-44167DDB-89FD-42D9-8B0E-C6B1739B7D84

Q26849417-9681CCA0-D8FA-4437-BFCC-3269C996B123

Q26849417-DAB7E211-AF9C-45F6-B856-6A3FA521A0EF

P2860

Q26849417-001D6382-C866-47BC-8BF2-7E2F7AB4DBF0

Q26849417-00389B14-C737-4142-B2EA-2095E4C0DA5D

Q26849417-007546D0-8847-4F81-BBFA-A2E7AC4A6C2A

Q26849417-009B3986-9FE1-430F-A881-02D3E8EB64DE

Q26849417-00AC43A6-78CC-4345-8360-CA199776DEC0

Q26849417-0108946B-CDAF-498B-BA84-5A763AA18071

Q26849417-0237F1AA-326D-46EE-AA0D-16F5A6A3B4BE

Q26849417-03821300-4752-4DD3-B80E-27E13E5A2BA0

Q26849417-038E53AD-30E1-4C81-ABC2-CC8FC8F38BBA

Q26849417-052C114B-92E4-4DCF-8276-B005F906A52E

P304

Q26849417-4F798301-07EE-46DB-9A36-5D8F48AF738C

P31

Q26849417-96B73AF9-A69B-4F45-8A92-09966F7742F1

P3181

Q26849417-C8968792-FCD3-4CF6-91D5-8D997096D846

P356

Q26849417-1AC73D23-E020-409F-8F55-7355F172916B

P407

Q26849417-FE572B79-587C-437D-A716-F4FD731A5157

P433

Q26849417-8A887C89-C2B8-439B-887C-E33D6E58C9EA

P478

Q26849417-A7F42A11-E422-448E-936C-625F27E59025

P577

Q26849417-5C1045AD-F1AB-47F4-8AD7-1552AD92505D

P698

Q26849417-F0099611-BBA3-4AB3-87FC-E96B46D8A589

P932

Q26849417-69D89146-05AA-47C1-83AB-876F7885576E

P3181

P356

P1433

British Journal of Pharmacology

P1476

Ten things you should know about protein kinases: IUPHAR Review 14

@en

P2093

Doriano Fabbro

http://www.w3.org/2001/XMLSchema#string

Henrik Moebitz

http://www.w3.org/2001/XMLSchema#string

Sandra W Cowan-Jacob

http://www.w3.org/2001/XMLSchema#string

P2860

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

Structural and functional diversity of the microbial kinome

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation

PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?

Cell cycle, CDKs and cancer: a changing paradigm

Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation

The protein kinase complement of the human genome

Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties

Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

P304

2675-700

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

281382

http://www.w3.org/2001/XMLSchema#string

P356

10.1111/BPH.13096

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

172

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25630872

http://www.w3.org/2001/XMLSchema#string

P932

4439867

http://www.w3.org/2001/XMLSchema#string